Cyberonics still defiant over four-time CMS rejection for anti-depression device
This article was originally published in Clinica
Executive Summary
Cyberonics has indicated it will not give up hope on getting its vagus nerve stimulation system reimbursed in the US for treatment-resistant depression (TRD) – even though its efforts to gain coverage have now been shot down for the fourth time.